Schaffer M, Schaffer P M, Vogesser M, Ertl-Wagner B, Rauch J, Oberneder R, Jori G, Hofstetter A, Dühmke E
Dept. of Radiation Therapy, University of Munich, Munich, Germany.
Photochem Photobiol Sci. 2002 Sep;1(9):686-9. doi: 10.1039/b203732g.
The effect of ionizing radiation on tumour tissues can be optimised by adding radiosensitising agents to enhance tumour inactivation. Photofrin II has been approved as a photosensitising agent for the photodynamic therapy (PDT) of selected solid tumours. At present, no chemical modifier has been found to act as a selective radiosensitiser. We report here the first use of Photofrin II as a radiosensitising agent to enhance radiation therapy.
Two patients, one female with unresectable bladder cancer and one male with recurrent inoperable bladder cancer, were treated with radiation therapy (44.8 Gy + 14 Gy boost) of the pelvic region. 24 hours before initiation of therapy the patients were intravenously injected with 1 mg kg(-1) Photofrin II (Axcan, Canada).
Magnetic resonance imaging of the pelvis with a standardized protocol demonstrated a reduction in tumour volume of approximately 40% in the female patient and 35% in the male patient. The female patient was operated upon after conclusion of radiotherapy, the male patient refused the operation. No severe side effects were observed.
Photofrin II is a promising radiosensitising agent in the treatment of patients with advanced solid tumours.
通过添加放射增敏剂来增强肿瘤灭活，可优化电离辐射对肿瘤组织的作用。卟吩姆钠已被批准作为特定实体瘤光动力疗法（PDT）的光敏剂。目前，尚未发现有化学修饰剂可作为选择性放射增敏剂。我们在此报告首次使用卟吩姆钠作为放射增敏剂来增强放射治疗。
两名患者，一名患有不可切除膀胱癌的女性和一名患有复发性不可手术膀胱癌的男性，接受了盆腔区域的放射治疗（44.8 Gy + 14 Gy加强剂量）。在治疗开始前24小时，给患者静脉注射1 mg·kg⁻¹的卟吩姆钠（Axcan，加拿大）。
采用标准化方案进行的盆腔磁共振成像显示，女性患者的肿瘤体积减少了约40%，男性患者减少了35%。放疗结束后，对女性患者进行了手术，男性患者拒绝手术。未观察到严重的副作用。
在晚期实体瘤患者的治疗中，卟吩姆钠是一种有前景的放射增敏剂。
